Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
IPO Year: 2022
Exchange: NASDAQ
Website: https://www.nuvectis.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/13/2022 | $21.00 | Buy | Ladenburg Thalmann |
3/2/2022 | $14.00 | Buy | HC Wainwright & Co. |
HC Wainwright & Co. analyst Joseph Pantginis reiterates Nuvectis Pharma (NASDAQ:NVCT) with a Buy and maintains $21 price target.
Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.40) by 37.5 percent. This is a 7.41 percent increase over losses of $(0.27) per share from the same period last year.
Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in TagrissoTMSingle Agent Antiproliferative Activity in Cells Resistant to Alectinib, the Active Ingredient in AlecensaTMFort Lee, NJ, April 08, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) today recapped poster highlights from the 2024 American Association for Cancer Research (AACR) conference demonstrating highly synergistic antiproliferative activity in epidermal growth factor receptor (EGFR)-resistant non-small cell lung cancer (NSCLC) cells of NXP900 in combination with osimertinib, the active ingredient in TagrissoTM, an EGFR inhibitor approved fo
Gainers Aptorum Gr (NASDAQ:APM) shares moved upwards by 47.1% to $6.37 during Thursday's pre-market session. The company's market cap stands at $33.0 million. Nuvectis Pharma (NASDAQ:NVCT) stock moved upwards by 23.65% to $11.92. The company's market cap stands at $211.8 million. Bright Green (NASDAQ:BGXX) stock moved upwards by 20.99% to $0.34. The market value of their outstanding shares is at $62.5 million. Unicycive Therapeutics (NASDAQ:UNCY) shares rose 14.38% to $1.59. The market value of their outstanding shares is at $55.2 million. Telomir Pharmaceuticals (NASDAQ:TELO) shares rose 13.57% to $8.2. The company's market cap stands at $251.0 million. Annexon (NASDAQ:ANNX) stock mov
33% Response Rate and 100% Disease Control Rate Observed in Patients Evaluated for EfficacyComplete Response of Non-Target Tumor Also ObservedPlatinum-Resistant Ovarian Cancer is a Devastating Serious Condition of Unmet Medical Need with a Median Life Expectancy of Approximately One Year
NUVECTIS PHARMA, INC.STATEMENT OF OPERATIONS(USD in thousands, except per share and share amounts)For the year endedFor the year endedDecember 31, 2023December 31, 2022OPERATING EXPENSES:Research and development15,38013,227General and administrative7,5176,007OPERATING LOSS(22,897)(19,234)Finance income637149NET LOSS(22,260)(19,085)NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS(22,260)(19,085)BASIC AND DILUTED NET LOSS PER COMMON SHARE OUTSTANDING(1.43)(1.51)Basic and diluted weighted average number of common shares outstanding15,556,65512,657,651
Gainers Celularity (NASDAQ:CELU) shares moved upwards by 44.7% to $0.27 during Thursday's regular session. The company's market cap stands at $52.8 million. NovoCure (NASDAQ:NVCR) shares increased by 24.15% to $15.42. The market value of their outstanding shares is at $1.6 billion. Jasper Therapeutics (NASDAQ:JSPR) shares moved upwards by 22.18% to $13.0. The market value of their outstanding shares is at $145.0 million. Nuvectis Pharma (NASDAQ:NVCT) shares moved upwards by 14.85% to $8.46. The company's market cap stands at $146.6 million. Bullfrog AI Hldgs (NASDAQ:BFRG) stock rose 14.74% to $3.66. The market value of their outstanding shares is at $22.3 million. Venus Concept (NASDAQ
Mitesh Borad, M.D., will serve as the Principal Investigator for the clinical trialThe Investigator-sponsored clinical trial follows the robust preclinical proof of concept data generated by investigators from Mayo Clinic in PDX models of cholangiocarcinoma (presented at the 2023 American Association for Cancer Research ("AACR"))NXP800 was granted orphan drug designation by the FDA for the treatment of cholangiocarcinoma in August 2023Fort Lee, NJ, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of
Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.34) by 8.82 percent. This is a 11.9 percent increase over losses of $(0.42) per share from the same period last year.
With its focus on targeting well-defined subgroups by inhibiting SRC/YES1 kinases in Non Small-Cell Lung Cancer patients resistant to EGFR and ALK targeted therapies, Nuvectis Pharma's NXP900 could hold similar transformative potential in NSCLC as Summit Therapeutics's Ivonescimab The Bottom Line Summit Therapeutics (NASDAQ:SMMT) recently reported Ivonescimab's Phase 3 results from study conducted in China that showed significant efficacy in addressing NSCLC treatment resistance, surpassing Merck's Keytruda in key outcomes and sending SMMT stock skyrocketing. Like Ivonescimab, Nuvectis Pharma's (NASDAQ:NVCT) NXP900 tackles resistance in NSCLC but targets a different pathway by inhibiti
Fort Lee, NJ, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference. EventH.C. Wainwright Global Investment ConferenceDateSeptember 9, 2024Time12:00 PM ETLinkhttps://journey.ct.events/view/5bacb2fb-d0c8-4efa-92b8-7365c030ddd5 About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development
FORT LEE, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that NXP800 was granted Orphan Drug Designation by the United States Food and Drug Administration ("FDA") for the treatment of AT-rich interactive domain-containing protein 1a (ARID1a) ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "We are very pleased to have received this designati
FORT LEE, N.J., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the second quarter 2024 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "During the second quarter we continued to advance our clinical trials for NXP800 and NXP900. For NXP800, the Phase 1b clinical trial in platinum resistant, ARID1a-mutated ovarian cancer is continuing to enroll
Fort Lee, NJ, May 16, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright 2nd BioConnect Investor Conference at the NASDAQ world headquarters in New York City. Event H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ Date May 20th, 2024 Time 12:00 PM Eastern Time Link Fireside Chat [Link] About Nuvectis Pharma, Inc. Nuvectis Pharma
Encouraging preliminary data announced from the NXP800 Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, a program granted Fast Track Designation by the US FDAData presented at the 2024 AACR demonstrate NXP900's robust activity in non-small cell cancer cell linesSeveral clinical data updates expected in 2H 2024 FORT LEE, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter 2024
Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in TagrissoTM Single Agent Antiproliferative Activity in Cells Resistant to Alectinib, the Active Ingredient in AlecensaTM Fort Lee, NJ, April 08, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) today recapped poster highlights from the 2024 American Association for Cancer Research (AACR) conference demonstrating highly synergistic antiproliferative activity in epidermal growth factor receptor (EGFR)-resistant non-small cell lung cancer (NSCLC) cells of NXP900 in combination with osimertinib, the active ingredient in TagrissoTM, an EGFR inh
Fort Lee, NJ, March 19, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming presentations for NXP800 and NXP900 at the upcoming 2024 American Association for Cancer Research Meeting (2024 AACR), taking place from April 5th to April 10th in San Diego, California. Presentation details are below: Abstract Title Poster Presentation Details NXP800 Pharmacokinetic and pharmacodynamic evaluation of NXP800, a novel GCN2 activator, in a first in hu
FORT LEE, NJ, March 15, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 36th Annual Roth Conference. Event 36th Annual Roth Conference Date March 19, 2024 Time 8:00 AM Pacific Time (11:00 AM Eastern Time) Link https://wsw.com/webcast/roth48/nvct/1852019 About Nuvectis Pharma Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the
33% Response Rate and 100% Disease Control Rate Observed in Patients Evaluated for EfficacyComplete Response of Non-Target Tumor Also Observed Platinum-Resistant Ovarian Cancer is a Devastating Serious Condition of Unmet Medical Need with a Median Life Expectancy of Approximately One Year Fort Lee, NJ, March 14, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) today announced preliminary data from the ongoing Phase 1b clinical trial of NXP800 in patients with platinum resistant ARID1a-mutated ovarian cancer, a deadly disease of unmet medical need. The NXP800 development program in this disease was granted Fast Track Designation by the U.S. Food and Drug Administra
8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
10-Q - Nuvectis Pharma, Inc. (0001875558) (Filer)
8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
10-Q - Nuvectis Pharma, Inc. (0001875558) (Filer)
8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
DEFA14A - Nuvectis Pharma, Inc. (0001875558) (Filer)
DEF 14A - Nuvectis Pharma, Inc. (0001875558) (Filer)
10-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
Ladenburg Thalmann initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $21.00
HC Wainwright & Co. initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $14.00
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13G - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13G - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13G - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13G - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13D - Nuvectis Pharma, Inc. (0001875558) (Subject)